M Toft

Summary

Affiliation: Norwegian University of Science and Technology
Country: Norway

Publications

  1. ncbi Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population
    M Toft
    Department of Neuroscience, Norwegian University of Science and Technology, N 7489 Trondheim, Norway
    Neurology 66:415-7. 2006
  2. ncbi MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease
    Linda R White
    Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
    J Neurosci Res 85:1288-94. 2007
  3. ncbi LRRK2 mutations are not common in Alzheimer's disease
    Mathias Toft
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL, USA
    Mech Ageing Dev 126:1201-5. 2005
  4. pmc PINK1 mutation heterozygosity and the risk of Parkinson's disease
    M Toft
    Department of Neuroscience, Norwegian University of Science and Technology NTNU, N 7489 Trondheim, Norway
    J Neurol Neurosurg Psychiatry 78:82-4. 2007
  5. doi Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population
    R Myhre
    Department of Laboratory Medicine, Children s and Women s Health, Norwegian University of Science and Technology, Trondheim, Norway
    Acta Neurol Scand 118:320-7. 2008
  6. ncbi LRRK2 and Parkinson's disease in Norway
    M Toft
    Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
    Acta Neurol Scand Suppl 187:72-5. 2007
  7. ncbi Lrrk2 R1441 substitution and progressive supranuclear palsy
    O A Ross
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
    Neuropathol Appl Neurobiol 32:23-5. 2006
  8. ncbi Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions
    Justus C Dachsel
    Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Acta Neuropathol 113:601-6. 2007
  9. ncbi Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease
    Mathias Toft
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA
    Mov Disord 22:389-92. 2007
  10. ncbi ELAVL4, PARK10, and the Celts
    Kristoffer Haugarvoll
    Department of Neuroscience and Neurology, Mayo Clinic College of Medicine, Jacksonville, Florida, USA
    Mov Disord 22:585-7. 2007

Collaborators

Detail Information

Publications24

  1. ncbi Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population
    M Toft
    Department of Neuroscience, Norwegian University of Science and Technology, N 7489 Trondheim, Norway
    Neurology 66:415-7. 2006
    ..Seven patients (2.3%) and 8 controls (1.7%) carried a mutant GBA allele (p = 0.58). This study does not indicate increased susceptibility to PD in GBA mutations carriers in Norway...
  2. ncbi MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease
    Linda R White
    Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
    J Neurosci Res 85:1288-94. 2007
    ..Such changes may also be shown in blood samples during the preclinical stage of LRRK2-associated PD, which could be particularly important for the development of neuroprotective strategies to delay onset, or slow progression of PD...
  3. ncbi LRRK2 mutations are not common in Alzheimer's disease
    Mathias Toft
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL, USA
    Mech Ageing Dev 126:1201-5. 2005
    ..However, these results do not exclude a possible role of other genetic variants within the LRRK2 gene in AD or other forms of dementia...
  4. pmc PINK1 mutation heterozygosity and the risk of Parkinson's disease
    M Toft
    Department of Neuroscience, Norwegian University of Science and Technology NTNU, N 7489 Trondheim, Norway
    J Neurol Neurosurg Psychiatry 78:82-4. 2007
    ..Mutations in the PTEN-induced kinase 1 (PINK1) gene have been identified in recessively inherited and sporadic early-onset parkinsonism (EOP)...
  5. doi Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population
    R Myhre
    Department of Laboratory Medicine, Children s and Women s Health, Norwegian University of Science and Technology, Trondheim, Norway
    Acta Neurol Scand 118:320-7. 2008
    ..Our aim was to study SNCA gene markers in a closely matched Norwegian PD population to examine the genetic relationship between different polymorphisms associated with the disease...
  6. ncbi LRRK2 and Parkinson's disease in Norway
    M Toft
    Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
    Acta Neurol Scand Suppl 187:72-5. 2007
    ..Herein, we investigate the frequency of a number of recently identified LRRK2 mutations in Norway...
  7. ncbi Lrrk2 R1441 substitution and progressive supranuclear palsy
    O A Ross
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
    Neuropathol Appl Neurobiol 32:23-5. 2006
    ..No evidence was found for the presence of a mutation at this codon in our series. These data would suggest that this Lrrk2 variant does not contribute in susceptibility to PSP...
  8. ncbi Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions
    Justus C Dachsel
    Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Acta Neuropathol 113:601-6. 2007
    ..These findings may be coincidental; however, there is a small nucleus of LRRK2-positive patients displaying atypical features suggesting a role for this protein in other neurodegenerative disorders...
  9. ncbi Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease
    Mathias Toft
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA
    Mov Disord 22:389-92. 2007
    ..3; 95% CI: 0.6-2.8; P = 0.45). These findings highlight the importance of using family-based studies and multiple population screenings when examining the association of these polymorphic LRRK2 gene variants with Parkinson's disease...
  10. ncbi ELAVL4, PARK10, and the Celts
    Kristoffer Haugarvoll
    Department of Neuroscience and Neurology, Mayo Clinic College of Medicine, Jacksonville, Florida, USA
    Mov Disord 22:585-7. 2007
    ..Our data suggest that the association between ELAVL4 and PD previously observed might be explained by a Celtic-founder effect...
  11. ncbi Clinical heterogeneity of the LRRK2 G2019S mutation
    Spiridon Papapetropoulos
    Department of Neurology, University of Miami School of Medicine, Miami, FL, USA
    Arch Neurol 63:1242-6. 2006
    ..The "common" LRRK2 G2019S kinase domain substitution has been reported to account for approximately 5% of familial and 1% of sporadic Parkinson disease...
  12. ncbi Lrrk2 and Lewy body disease
    Owen A Ross
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
    Ann Neurol 59:388-93. 2006
    ..The Lrrk2 kinase domain G2019S substitution is the most common genetic basis of familial and sporadic parkinsonism. Patients harboring the G2019S substitution usually present with clinical Parkinson's disease...
  13. pmc Genomewide association, Parkinson disease, and PARK10
    Matthew J Farrer
    Am J Hum Genet 78:1084-8; author reply 1092-4. 2006
  14. ncbi Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD
    David Gosal
    Department of Neurology, Mater Misericordiae Hospital, Eccles St, Dublin 7, Ireland
    Parkinsonism Relat Disord 11:349-52. 2005
    ..The influence of the G2019S substitution on protein function and disease phenotype has yet to be fully resolved, but its elucidation will undoubtedly further our understanding of the mechanisms underlying Parkinson's disease...
  15. ncbi Clinical features of LRRK2-associated Parkinson's disease in central Norway
    Jan O Aasly
    Department of Neurology, St Olav s Hospital, Trondheim, Norway
    Ann Neurol 57:762-5. 2005
    ..The clinical features included asymmetric resting tremor, bradykinesia, and rigidity with a good response to levodopa and could not be distinguished from idiopathic Parkinson's disease...
  16. ncbi LRRK2 mutations and Parkinsonism
    Mathias Toft
    Lancet 365:1229-30. 2005
  17. pmc Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations
    Jennifer Kachergus
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
    Am J Hum Genet 76:672-80. 2005
    ..Our work highlights the fact that a proportion of clinically typical, late-onset PD cases have a genetic basis...
  18. doi Corticobasal syndrome and primary progressive aphasia as manifestations of lrrk2 gene mutations
    Owen A Ross
    Neurology 71:303; author reply 303-4. 2008
  19. ncbi Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway
    Kristoffer Haugarvoll
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA, and Department of Neurology, St Olav s Hospital, Trondheim, Norway
    Neurosci Lett 416:299-301. 2007
    ..Two rare coding variants ss65713826 and ss65713830 were more frequent in patients than controls. However, their identification in healthy controls and lack of co-segregation with disease suggests they may represent benign polymorphisms...
  20. ncbi [The genetics of Parkinson disease]
    Mathias Toft
    Institutt for nevromedisin, Det medisinske fakultet, Norges Teknisk Naturvitenskapelige Universitet
    Tidsskr Nor Laegeforen 124:922-4. 2004
    ..Parkinson's disease, PD, is the second most common neurodegenerative disorder. A genetic component in Parkinson's disease was long thought to be unlikely, but recent genetic studies have identified several genes associated with the disease...
  21. ncbi [Malignant hyperthermia--a hereditary and potentially life-threatening condition]
    Tonje Haugen
    Department of Public Health, University of North Florida, USA
    Tidsskr Nor Laegeforen 125:2792-4. 2005
    ..Susceptibility to malignant hyperthermia is inherited as an autosomal dominant disorder and is associated with myopathies...
  22. ncbi FMR1 premutations associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophy
    Valerie Biancalana
    Institut de Genetique et de Biologie Moleculaire et Cellulaire, Strasburg, France
    Arch Neurol 62:962-6. 2005
    ..It has been proposed that FXTAS might be a common neurodegenerative disorder...
  23. pmc Linkage disequilibrium and association of MAPT H1 in Parkinson disease
    Lisa Skipper
    Laboratories of Neurogenetics, Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
    Am J Hum Genet 75:669-77. 2004
    ..Using a sliding scale of MAPT H1-specific haplotypes--in age/sex-matched PD cases and controls from central Norway--we have refined the disease association to within an approximately 90-kb interval of the 5' end of the MAPT locus...
  24. ncbi [Treatment of movement disorders with deep brain stimulation]
    Mathias Toft
    Nevrologisk avdeling, Nevroklinikken, Rikshospitalet, 0027 Oslo
    Tidsskr Nor Laegeforen 128:1972-6. 2008
    ..We also present data om the activity related to patients with Parkinson's disease in a representative year and data on implantations performed Rikshospitalet University Hospital in the period 1999-2007...